Bedfont Scientific Recognizes World Asthma Day, Manufactures NObreath FeNO Test – Lung Disease News


Lung Disease News

Bedfont Scientific Recognizes World Asthma Day, Manufactures NObreath FeNO Test
Lung Disease News
United Kingdom-based Bedfont Scientific, which is celebrating four decades in business this year, is recognizing World Asthma Day on May. The company manufactures NObreath FeNO Test, a fractional exhaled nitric oxide (FeNO) breath analysis monitoring …

View full post on asthma – Google News

A pathophysiological approach for FeNO: A biomarker for asthma.

A pathophysiological approach for FeNO: A biomarker for asthma.

Allergol Immunopathol (Madr). 2015 Mar 18;

Authors: Ricciardolo FL, Sorbello V, Ciprandi G

Abstract
The present review is focused on literature concerning the relevance of fractional exhaled nitric oxide (FeNO) in clinical practice from a pathophysiological point of view. There is increasing evidence that asthma is a heterogeneous pathological condition characterised by different phenotypes/endotypes related to specific biomarkers, including FeNO, helpful to predict therapeutic response in selected asthmatic populations. Nowadays FeNO, a non-invasive biomarker, appears to be useful to foresee asthma developing, to recognise specific asthma phenotypes, like the eosinophilic, to ameliorate asthma diagnosis and management in selected populations and to predict standard corticosteroid and biologic therapy efficacy. In addition, FeNO assessment may also be useful in patients with allergic rhinitis in order to detect the potential involvement of eosinophilic bronchial inflammation in “case finding” subjects at risk of asthma diagnosis. Therefore, it is possible to hypothesise a future with an appropriate use of FeNO by physicians dealing with worrisome clinical issues in specific asthma phenotypes.

PMID: 25796309 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

NICE backs FeNO devices for asthma diagnosis – Nursing Times


Gloucestershire Echo

NICE backs FeNO devices for asthma diagnosis
Nursing Times
It has recommended three devices – NIOX MINO, NIOX VERO and NObreath – to measure the levels of fractional-exhaled nitric oxide (FeNO) a patient is breathing out that are indicative of inflammation associated with asthma. The institute's guidance …
Asthma sufferers recommended breath test pioneered in GloucestershireGloucestershire Echo
Search for jobs in the North EastThe Journal

all 3 news articles »

View full post on asthma – Google News

Aerocrine: BlueCross BlueShield of Minnesota to begin FeNO Coverage in August – Business Wire (press release)

Aerocrine: BlueCross BlueShield of Minnesota to begin FeNO Coverage in August
Business Wire (press release)
Following the transition period, exhaled nitric oxide measurement (CPT code 95012) will be covered for patients with asthma. BlueCross BlueShield of Minnesota is the largest insurance company in the state and provides coverage to approximately 66

and more »

View full post on asthma – Google News